Topic: triple-negative breast cancer
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Merck and OncoSec partnered on a second immunotherapy combination, now in triple-negative breast cancer, following a melanoma study last year.
The funding will see Quentis' lead immunotherapy candidate into the clinic in 2019.
After disappointing data in leukemia, France’s Erytech is refocusing its red blood cell-encapsulated drug therapy to solid tumors.
A stem cell pathway could be targeted to create more effective treatments for triple-negative breast cancer.
Bicycle Therapeutics has returned to its big name backers for £40 million to fund the advance of cancer candidates into the clinic.
Two phase 3 trials of AbbVie’s PARP inhibitor veliparib have missed their primary endpoints.
VenBio has criticized the timing and terms of Immunomedics’ licensing deal with Seattle Genetics.
Immunomedics says new data for lead drug IMMU-132 in triple-negative breast cancer keep it on course to file for accelerated approval in mid-2017.
Seattle Genetics could move beyond its core focus in blood cancers and into the solid tumor setting, if positive early-stage data is backed up by further trials.